Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy

B. Holkova, K. Takeshita, D. M. Cheng, M. Volm, C. Wasserheit, R. Demopoulos, Asher A Chanan Khan

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Purpose: Kaposi's sarcoma (KS) is the most common AIDS-related malignancy. Pulmonary involvement by KS (PKS) has carried a poor prognosis with median reported survival ranging from 3 to 10 months. We studied whether the introduction of highly active antiretroviral therapy (HAART; triple antiretroviral therapy including a protease inhibitor and two reverse transcriptase inhibitors) has been associated with improved survival for AIDS patients with PKS. Patients and Methods: A retrospective study was performed of 37 consecutive patients with PKS and human immunodeficiency virus infection in the tumor registry at a large municipal hospital in New York City between 1994 to 1997. There were 16 patients from 1994 to 1995 (pre-HAART period) and 21 patients from 1996 to 1997 (post-HAART period). The primary end point was survival, which was defined as time from start of chemotherapy until death from any cause. Results: Patients were analyzed by the date of diagnosis (pre- v post-HAART period) and whether or not they received HAART. Kaplan-Meier analysis showed significantly better survival in patients diagnosed in the post-HAART period (P = .0025). Additional Kaplan-Meier analysis indicated that patients on HAART had substantially better survival (P < .0001). Cox multivariate analyses showed that HAART therapy was associated with a reduced risk of death (hazard ratio = 0.09; 95% confidence interval, 0.03 to 0.69). Conclusion: In patients with AIDS-associated PKS and undergoing chemotherapy, administration of HAART was associated with increased survival.

Original languageEnglish (US)
Pages (from-to)3848-3851
Number of pages4
JournalJournal of Clinical Oncology
Volume19
Issue number18
StatePublished - Sep 15 2001
Externally publishedYes

Fingerprint

Kaposi's Sarcoma
Highly Active Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Drug Therapy
Lung
Survival
Kaplan-Meier Estimate
Municipal Hospitals
Reverse Transcriptase Inhibitors
Virus Diseases
Protease Inhibitors
Registries
Cause of Death
Neoplasms
Multivariate Analysis
Retrospective Studies
HIV
Confidence Intervals

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. / Holkova, B.; Takeshita, K.; Cheng, D. M.; Volm, M.; Wasserheit, C.; Demopoulos, R.; Chanan Khan, Asher A.

In: Journal of Clinical Oncology, Vol. 19, No. 18, 15.09.2001, p. 3848-3851.

Research output: Contribution to journalArticle

Holkova, B. ; Takeshita, K. ; Cheng, D. M. ; Volm, M. ; Wasserheit, C. ; Demopoulos, R. ; Chanan Khan, Asher A. / Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. In: Journal of Clinical Oncology. 2001 ; Vol. 19, No. 18. pp. 3848-3851.
@article{2d1fa554295c40b59fbcf905b6b1aee7,
title = "Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy",
abstract = "Purpose: Kaposi's sarcoma (KS) is the most common AIDS-related malignancy. Pulmonary involvement by KS (PKS) has carried a poor prognosis with median reported survival ranging from 3 to 10 months. We studied whether the introduction of highly active antiretroviral therapy (HAART; triple antiretroviral therapy including a protease inhibitor and two reverse transcriptase inhibitors) has been associated with improved survival for AIDS patients with PKS. Patients and Methods: A retrospective study was performed of 37 consecutive patients with PKS and human immunodeficiency virus infection in the tumor registry at a large municipal hospital in New York City between 1994 to 1997. There were 16 patients from 1994 to 1995 (pre-HAART period) and 21 patients from 1996 to 1997 (post-HAART period). The primary end point was survival, which was defined as time from start of chemotherapy until death from any cause. Results: Patients were analyzed by the date of diagnosis (pre- v post-HAART period) and whether or not they received HAART. Kaplan-Meier analysis showed significantly better survival in patients diagnosed in the post-HAART period (P = .0025). Additional Kaplan-Meier analysis indicated that patients on HAART had substantially better survival (P < .0001). Cox multivariate analyses showed that HAART therapy was associated with a reduced risk of death (hazard ratio = 0.09; 95{\%} confidence interval, 0.03 to 0.69). Conclusion: In patients with AIDS-associated PKS and undergoing chemotherapy, administration of HAART was associated with increased survival.",
author = "B. Holkova and K. Takeshita and Cheng, {D. M.} and M. Volm and C. Wasserheit and R. Demopoulos and {Chanan Khan}, {Asher A}",
year = "2001",
month = "9",
day = "15",
language = "English (US)",
volume = "19",
pages = "3848--3851",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18",

}

TY - JOUR

T1 - Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy

AU - Holkova, B.

AU - Takeshita, K.

AU - Cheng, D. M.

AU - Volm, M.

AU - Wasserheit, C.

AU - Demopoulos, R.

AU - Chanan Khan, Asher A

PY - 2001/9/15

Y1 - 2001/9/15

N2 - Purpose: Kaposi's sarcoma (KS) is the most common AIDS-related malignancy. Pulmonary involvement by KS (PKS) has carried a poor prognosis with median reported survival ranging from 3 to 10 months. We studied whether the introduction of highly active antiretroviral therapy (HAART; triple antiretroviral therapy including a protease inhibitor and two reverse transcriptase inhibitors) has been associated with improved survival for AIDS patients with PKS. Patients and Methods: A retrospective study was performed of 37 consecutive patients with PKS and human immunodeficiency virus infection in the tumor registry at a large municipal hospital in New York City between 1994 to 1997. There were 16 patients from 1994 to 1995 (pre-HAART period) and 21 patients from 1996 to 1997 (post-HAART period). The primary end point was survival, which was defined as time from start of chemotherapy until death from any cause. Results: Patients were analyzed by the date of diagnosis (pre- v post-HAART period) and whether or not they received HAART. Kaplan-Meier analysis showed significantly better survival in patients diagnosed in the post-HAART period (P = .0025). Additional Kaplan-Meier analysis indicated that patients on HAART had substantially better survival (P < .0001). Cox multivariate analyses showed that HAART therapy was associated with a reduced risk of death (hazard ratio = 0.09; 95% confidence interval, 0.03 to 0.69). Conclusion: In patients with AIDS-associated PKS and undergoing chemotherapy, administration of HAART was associated with increased survival.

AB - Purpose: Kaposi's sarcoma (KS) is the most common AIDS-related malignancy. Pulmonary involvement by KS (PKS) has carried a poor prognosis with median reported survival ranging from 3 to 10 months. We studied whether the introduction of highly active antiretroviral therapy (HAART; triple antiretroviral therapy including a protease inhibitor and two reverse transcriptase inhibitors) has been associated with improved survival for AIDS patients with PKS. Patients and Methods: A retrospective study was performed of 37 consecutive patients with PKS and human immunodeficiency virus infection in the tumor registry at a large municipal hospital in New York City between 1994 to 1997. There were 16 patients from 1994 to 1995 (pre-HAART period) and 21 patients from 1996 to 1997 (post-HAART period). The primary end point was survival, which was defined as time from start of chemotherapy until death from any cause. Results: Patients were analyzed by the date of diagnosis (pre- v post-HAART period) and whether or not they received HAART. Kaplan-Meier analysis showed significantly better survival in patients diagnosed in the post-HAART period (P = .0025). Additional Kaplan-Meier analysis indicated that patients on HAART had substantially better survival (P < .0001). Cox multivariate analyses showed that HAART therapy was associated with a reduced risk of death (hazard ratio = 0.09; 95% confidence interval, 0.03 to 0.69). Conclusion: In patients with AIDS-associated PKS and undergoing chemotherapy, administration of HAART was associated with increased survival.

UR - http://www.scopus.com/inward/record.url?scp=0035884224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035884224&partnerID=8YFLogxK

M3 - Article

C2 - 11559722

AN - SCOPUS:0035884224

VL - 19

SP - 3848

EP - 3851

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 18

ER -